Literature DB >> 29550971

Talking Points: Women's Information Needs for Informed Decision-Making About Noninvasive Prenatal Testing for Down Syndrome.

Aimée C Dane1,2, Madelyn Peterson1, Yvette D Miller3.   

Abstract

Adequate knowledge is a vital component of informed decision-making; however, we do not know what information women value when making decisions about noninvasive prenatal testing (NIPT). The current study aimed to identify women's information needs for decision-making about NIPT as a first-tier, non-contingent test with out-of-pocket expense and, in turn, inform best practice by specifying the information that should be prioritized when providing pre-test counseling to women in a time-limited scenario or space-limited decision support tool. We asked women (N = 242) in Australia to indicate the importance of knowing 24 information items when making a decision about NIPT and to choose two information items they would most value. Our findings suggest that women value having complete information when making decisions about NIPT. Information about the accuracy of NIPT and the pros and cons of NIPT compared to other screening and invasive tests were perceived to be most important. The findings of this study can be used to maximize the usefulness of time-limited discussions or space-limited decision support tools, but should not be routinely relied upon as a replacement for provision of full and tailored information when feasible.

Entities:  

Keywords:  Cell-free fetal DNA; Decision-making; Down syndrome; Informed consent; Noninvasive prenatal screening; Noninvasive prenatal testing; Patient education; Patient knowledge; Prenatal screening; cffDNA

Mesh:

Year:  2018        PMID: 29550971     DOI: 10.1007/s10897-018-0250-8

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  29 in total

1.  Informed decision-making in prenatal screening for Down's syndrome: what knowledge is relevant?

Authors:  H M H J D Schoonen; H M E van Agt; M L Essink-Bot; H I Wildschut; E A P Steegers; H J de Koning
Journal:  Patient Educ Couns       Date:  2010-08-25

2.  The role of attitudes towards the targets of behaviour in predicting and informing prenatal testing choices.

Authors:  Louise D Bryant; Josephine M Green; Jenny Hewison
Journal:  Psychol Health       Date:  2010-12

Review 3.  Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy.

Authors: 
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

4.  Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testing.

Authors:  M A Allyse; L C Sayres; M Havard; J S King; H T Greely; L Hudgins; J Taylor; M E Norton; M K Cho; D Magnus; K E Ormond
Journal:  Prenat Diagn       Date:  2013-05-21       Impact factor: 3.050

5.  NIPT and Informed Consent: an Assessment of Patient Understanding of a Negative NIPT Result.

Authors:  Julie L Piechan; Karrie A Hines; Daniel L Koller; Kristyne Stone; Kimberly Quaid; Wilfredo Torres-Martinez; Divya Wilson Mathews; Tatiana Foroud; Lola Cook
Journal:  J Genet Couns       Date:  2016-04-01       Impact factor: 2.537

6.  Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective.

Authors:  Amy Sachs; Leah Blanchard; Amanda Buchanan; Errol Norwitz; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2015-09-03       Impact factor: 3.050

7.  NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Authors:  K L Wilson; J L Czerwinski; J M Hoskovec; S J Noblin; C M Sullivan; A Harbison; M W Campion; K Devary; P Devers; C N Singletary
Journal:  J Genet Couns       Date:  2012-11-22       Impact factor: 2.537

8.  Non-invasive prenatal testing for Down's syndrome: pregnant women's views and likely uptake.

Authors:  C Lewis; C Silcock; L S Chitty
Journal:  Public Health Genomics       Date:  2013-07-25       Impact factor: 2.000

9.  Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol.

Authors:  Melissa Hill; David Wright; Rebecca Daley; Celine Lewis; Fiona McKay; Sarah Mason; Nicholas Lench; Abigail Howarth; Christopher Boustred; Kitty Lo; Vincent Plagnol; Kevin Spencer; Jane Fisher; Mark Kroese; Stephen Morris; Lyn S Chitty
Journal:  BMC Pregnancy Childbirth       Date:  2014-07-16       Impact factor: 3.007

10.  Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy.

Authors:  Celine Lewis; Melissa Hill; Heather Skirton; Lyn S Chitty
Journal:  Eur J Hum Genet       Date:  2015-10-28       Impact factor: 4.246

View more
  4 in total

1.  External Quality Assessment of Maternal Serum Levels of Alpha-Fetoprotein, Free Beta-Human Chorionic Gonadotropin, and Unconjugated Estriol in Detecting Down Syndrome and Neural Tube Defects in the Second Trimester of 87 Maternal Serum Samples, Based on 105-139 Days.

Authors:  Yiming Chen; Yijie Chen; Yezhen Shi; Wenwen Ning; Xiaoying Wang; Liyao Li; Huimin Zhang
Journal:  Med Sci Monit       Date:  2022-04-13

2.  Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China.

Authors:  Yanhui Liu; Hailiang Liu; Yi He; Wanfang Xu; Qiulin Ma; Yuzhen He; Wei Lei; Guoquan Chen; Zheng He; Jiayi Huang; Jianan Liu; Yuanru Liu; Quanfei Huang; Fubing Yu
Journal:  Hum Genomics       Date:  2020-06-05       Impact factor: 4.639

3.  The influence of experiential knowledge and societal perceptions on decision-making regarding non-invasive prenatal testing (NIPT).

Authors:  Sophie Montgomery; Zaneta M Thayer
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-19       Impact factor: 3.007

4.  Service provision of non-invasive prenatal testing for Down syndrome in public and private healthcare sectors: a qualitative study with obstetric providers.

Authors:  Olivia Miu Yung Ngan; Huso Yi; Shenaz Ahmed
Journal:  BMC Health Serv Res       Date:  2018-09-21       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.